Nina Schooler

Suggest Changes
John M. Kane67
Stephen R. Marder37
Delbert G Robinson31
Kim T. Mueser31
Robert W. Buchanan26
81John M. Kane
40Stephen R. Marder
38Christoph U. Correll
38Delbert G Robinson
36Kim T. Mueser

Filter Results:

  • Full text PDF available (29)

Publication Year

1966
2017
  • This year (9)
  • Last 5 years (41)
  • Last 10 years (58)

Publication Type

Co-author

Publication Venue

Brain Region

Cell Type

Key Phrases

Method

Organism

Learn More
Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications.
OBJECTIVE To assess the effects of modafinil on fatigue, symptoms, attention, working memory, and executive functioning in schizophrenia patients treated with psychotropic medications. METHOD Twenty-four patients with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder (10 men and 14 women) were randomly assigned to modafinil up to 200 mg a… (More)
Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia.
OBJECTIVE Because reduction of psychotic symptoms in schizophrenia does not result in adequate community functioning, efforts have shifted to other areas, such as cognitive impairment. The U.S. Food and Drug Administration requires that drugs for cognition enhancement in schizophrenia show improvement on two distinct outcome measures in clinical trials: an… (More)
Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible?
Accumulating evidence suggests alterations in brain structure, especially in the prefrontal and temporal cortex, in schizophrenia. Previous studies examining the progression of brain structural alterations in schizophrenia have led to conflicting results. Morphometric studies of the superior temporal gyrus (STG) volumes were conducted in a series of… (More)
Diagnostic specificity and neuroanatomical validity of neurological abnormalities in first-episode psychoses.
OBJECTIVE Neurological abnormalities are frequently seen in patients with first-episode psychotic disorders but are generally considered to be diagnostically nonspecific, neurologically nonlocalizing, and, hence, "soft." This study examined the neuroanatomical correlates and diagnostic specificity of abnormal findings on the neurological examination in… (More)
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.
OBJECTIVE To develop treatment recommendations for the use of antipsychotic medications for children and adolescents with serious psychiatric disorders and externalizing behavior problems. METHOD Using a combination of evidence- and consensus-based methodologies, recommendations were developed in six phases as informed by three primary sources of… (More)
Physical health monitoring of patients with schizophrenia.
OBJECTIVE Schizophrenia is associated with several chronic physical illnesses and a shorter life expectancy, compared with life expectancy in the general population. One approach to improving the health of patients with schizophrenia is to improve the monitoring of physical health that occurs in psychiatric settings. The authors discuss a consensus panel's… (More)
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
OBJECTIVE Patients with schizophrenia frequently present with negative symptoms and cognitive impairments for which no effective treatments are known. Agents that act at the glycine site of the N-methyl-D-aspartic acid (NMDA) glutamatergic receptor have been suggested as promising treatments for moderate to severe negative symptoms and cognitive… (More)
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
OBJECTIVE The first episode of psychotic illness is a key intervention point. The initial experience with medication can affect willingness to accept treatment. Further, relapse prevention is a treatment cornerstone during the first years of illness because active psychotic illness may affect lifetime outcomes. Thus, initial treatment of active symptoms and… (More)
Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
BACKGROUND Previous studies have examined dose reduction and family treatment in schizophrenia, but none has examined their interaction. This study assessed the impact of dose reduction of antipsychotic medication and family treatment on relapse and rehospitalization during maintenance treatment. METHODS Subjects were 313 male and female outpatients at 5… (More)
Predictors of acute dystonia in first-episode psychotic patients.
Sixty-two first-episode psychotic patients who were neuroleptic-naive were studied to examine predictors of acute dystonia after treatment with haloperidol. Twenty-three patients developed dystonia, two of them despite being treated with biperiden. Biperiden significantly prevented dystonic reactions. Dystonia development was significantly related to… (More)